GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
By Elana Gotkine HealthDay Reporter
MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening depressive symptoms, according to a study published online May 14 in JAMA Psychiatry.
Aureliane C.S. Pierret, M.B.B.Chir., from Guy's and St. Thomas' NHS Foundation Trust in London, and colleagues conducted a meta-analysis of randomized, placebo-controlled trials to examine psychiatric, cognitive, and quality of life (QOL) outcomes with GLP-1 RA treatment in adults with overweight/obesity and/or diabetes. The meta-analysis included 107,860 patients from 80 randomized clinical trials.
The researchers found that GLP-1 RA treatment was not associated with a significant difference in the risk for serious psychiatric adverse events and nonserious psychiatric adverse events, or depressive symptom change, versus placebo. There were associations for GLP-1 RA treatment versus placebo with improvements in restrained eating and emotional eating behavior (Hedges g = 0.35 and 0.32) and in mental health-related QOL, physical health-related QOL, diabetes-related QOL, and weight-related QOL (Hedges g = 0.15, 0.20, 0.23, and 0.27, respectively).
"Our results provide reassurance regarding the psychiatric safety profile of GLP-1 RAs and suggest that GLP-1 RA treatment is associated with improved mental well-being, in addition to the known physical health improvements," the authors write.
Several authors disclosed ties to the biopharmaceutical and publishing industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...
Prevalence of Extremely Severe Obesity Increasing in Children
TUESDAY, July 22, 2025 -- From 2008 to 2023, there was an increase in the prevalence of extremely severe obesity in children, especially among older adolescents and non-Hispanic...
ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes
FRIDAY, July 18, 2025 -- In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.